drugset / Trial / NCT00181558
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
Phase 2
Completed
44 enrolled
Massachusetts General Hospital
Abbott · collabBrigham and Women's Hospital · collabDana-Farber Cancer Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread to the bones.
Timeline
- Start
- 2001-12
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atrasentan | Other / unclassified | — | Oral |
| Subject | Zoledronic acid | Other / unclassified | — | Intravenous |